Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 NeutriSci InternationalAequus PharmaceuticalsSugarBud Craft GrowersEvgen PharmaLattice Biologics
SymbolCVE:NUCVE:AQSCVE:SUGRLON:EVGCVE:LBL
Price Information
Current PriceC$0.19C$0.22C$0.06GBX 8.50C$0.05
52 Week RangeN/AN/AN/AN/AN/A
MarketRank™
Overall Score0.50.90.70.90.5
Analysis Score0.00.00.00.00.0
Community Score2.52.62.93.02.7
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.01.70.0
Earnings & Valuation Score0.00.00.60.00.0
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/AN/A
Consensus Price TargetN/AN/AN/AN/AN/A
% Upside from Price TargetN/AN/AN/AN/AN/A
Trade Information
Market CapC$8.65 millionC$6.03 millionC$11.81 million£23.37 millionC$4.67 million
BetaN/AN/AN/AN/AN/A
Average Volume660,400726,0822,874,4401,820,687637,478
Sales & Book Value
Annual RevenueC$69,626.00C$2.28 millionC$66,906.00£194,000.00C$2.24 million
Price / Sales416.0512.65442.87120.442.86
CashflowC$0.00 per shareC$0.02 per shareC$0.00 per shareGBX 1.70 per shareN/A
Price / Cash95.0010.4816.675.00N/A
Book ValueC$0.00 per shareC$0.01 per shareC$5.73 per shareGBX 1.90 per shareC($0.05) per share
Price / Book95.0036.670.010.04-0.96
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSC($0.01)C($0.02)C($1.79)GBX (2.10)C($0.02)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E Ratio
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio3.87%383.77%61.07%N/AN/A
Current Ratio1.09%4.19%1.36%6.71%0.10%
Quick Ratio0.35%3.76%0.52%6.71%0.03%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
EmployeesN/A10199N/A
Shares Outstanding152.46 million130.93 million538.73 million274.89 million128.22 million
Next Earnings DateN/A6/7/2021 (Estimated)N/A6/14/2021 (Estimated)6/1/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Lattice Announces Strategic Advisory BoardLattice Announces Strategic Advisory Board
finance.yahoo.com - March 31 at 7:46 AM
Lattice Announces Strategic Cannabis Supply Agreement With FirehouseLattice Announces Strategic Cannabis Supply Agreement With Firehouse
finance.yahoo.com - March 19 at 12:25 PM
Lattice Biologics Reorganizes to Focus on Psychedelics and Cannabis TherapiesLattice Biologics Reorganizes to Focus on Psychedelics and Cannabis Therapies
finance.yahoo.com - March 15 at 10:00 AM
Lattice Biologics Ltd. Announces Resignation of DirectorLattice Biologics Ltd. Announces Resignation of Director
uk.finance.yahoo.com - March 3 at 6:45 PM
Lattice Biologics Ltd. Reports First Quarter 2021 HighlightsLattice Biologics Ltd. Reports First Quarter 2021 Highlights
apnews.com - March 1 at 11:40 PM
Lattice Biologics Ltd. Reports Fourth Quarter and Year End 2020 HighlightsLattice Biologics Ltd. Reports Fourth Quarter and Year End 2020 Highlights
apnews.com - January 28 at 11:45 PM
Global Spine Biologics Market Analysis With Key Players, Applications, Trends And Forecasts 2028Global Spine Biologics Market Analysis With Key Players, Applications, Trends And Forecasts 2028
pharmiweb.com - January 19 at 6:56 PM
Depth Filtration Market Research By Key Players, Type And Application, Future Growth To 2026Depth Filtration Market Research By Key Players, Type And Application, Future Growth To 2026
marketwatch.com - December 14 at 8:50 AM
News for Lattice Biologics LtdNews for Lattice Biologics Ltd
markets.businessinsider.com - December 2 at 3:48 AM
COVID19 UPDATE - Lattice Biologics Announces Cessation of Patient RecruitmentCOVID19 UPDATE - Lattice Biologics Announces Cessation of Patient Recruitment
stockhouse.com - September 4 at 3:37 PM
Lattice Biologics Ltd. Reports Q3 2020 ResultsLattice Biologics Ltd. Reports Q3 2020 Results
businesswire.com - August 31 at 8:11 PM
Lattice Biologics Issues Shares and WarrantsLattice Biologics Issues Shares and Warrants
financialpost.com - August 18 at 10:58 AM
Lattice Biologics Ltd. (LBLTF)Lattice Biologics Ltd. (LBLTF)
finance.yahoo.com - August 14 at 12:26 PM
What Did Lattice Biologics (CVE:LBL) CEO Take Home Last Year?What Did Lattice Biologics' (CVE:LBL) CEO Take Home Last Year?
finance.yahoo.com - July 23 at 8:34 AM
Lattice Biologics Eliminates CAN$838,000 in DebtLattice Biologics Eliminates CAN$838,000 in Debt
business.financialpost.com - June 8 at 7:31 PM
Lattice Biologics Ltd LBLTFLattice Biologics Ltd LBLTF
stockhouse.com - June 6 at 10:56 PM
Lattice Biologics Ltd. Reports Second Quarter 2020 ResultsLattice Biologics Ltd. Reports Second Quarter 2020 Results
business.financialpost.com - June 2 at 1:28 PM
190,524190,524
www.businesswire.com - June 2 at 1:28 PM
Lattice Biologics UpdateLattice Biologics Update
www.businesswire.com - May 11 at 4:04 PM
Lattice Biologics Ltd V.LBLLattice Biologics Ltd V.LBL
stockhouse.com - April 28 at 2:04 AM
Health-Related Concerns Have Exciting, Stock-Moving NewsHealth-Related Concerns Have Exciting, Stock-Moving News
www.baystreet.ca - April 15 at 5:28 PM
Lattice Biologics Ltd. Announces Option RepricingLattice Biologics Ltd. Announces Option Repricing
finance.yahoo.com - April 15 at 5:28 PM
Lattice Biologics Ltd. Announces Initial Recruitment of Patients for a Phase 1 Clinical Trial to ...Lattice Biologics Ltd. Announces Initial Recruitment of Patients for a Phase 1 Clinical Trial to ...
www.fortsaskatchewanrecord.com - March 17 at 1:09 PM
Business Wire | Windsor StarBusiness Wire | Windsor Star
windsorstar.com - March 16 at 7:49 AM
Lattice Biologics to Evaluate Anti-Inflammatory Stem Cell Therapy Treatment of COVID-19 Lung DiseaseLattice Biologics to Evaluate Anti-Inflammatory Stem Cell Therapy Treatment of COVID-19 Lung Disease
business.financialpost.com - March 13 at 7:26 AM
DateCompanyBrokerageAction
4/18/2019SugarBud Craft GrowersFundamental ResearchInitiated Coverage
6/15/2020Evgen PharmaFinnCapReiterated Rating
12/12/2018Evgen PharmaNorthland SecuritiesReiterated Rating
(Data available from 4/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.